HST Global Announces Formalization of Protocol Licensing for International Partnerships
April 29 2010 - 8:30AM
Business Wire
HST Global, Inc. (OTCBB: HSTC) today announced that it has
finalized the formal licensing model that will be used by our
international partners in the development of our Clinical Treatment
Facilities worldwide.
As previously announced, HST Global Inc. (HST) has partnered
with Health Matters International (HMI), a Canadian Company that
has vast international knowledge in the Healthcare Industry.
Through this association, HMI identified Panama and Costa Rica as
potential countries for the development of HST’s Clinical Treatment
Facilities which features the company’s “FIT” protocol. Doctors
that will have a role as part of the initial medical team in these
clinics recently visited the prototype facility in Reno.
Licensing fees will range between $250,000 and $500,000 and will
be measured against the “drawing” population of the location. While
other factors will be involved in each individual country such as
demographic data and economic circumstances, the fee will
incorporate training, initial products and onsite development for
each respective team. In addition, HST will be paid a royalty
amount for each application of the Company’s protocol.
Mr. Ron Howell, CEO and President of HST Global, Inc., stated,
“We are pleased with the progress we have made formalizing our
licensing model for our global partners. Greg and his team at HMI
are ready to introduce this successful protocol to patients in both
Panama and Costa Rica. HST has received a number of international
inquires regarding the opening of clinics. While the completion of
this formal licensing model will allow the company to proceed with
these opportunities, the major consideration is facilitating growth
with continuity in presentation and application of the “FIT”
protocol to ensure maximum success among the community of patients
we serve.”
Mr. Wes Tate, CFO of HST Global, Inc., stated, “It is exciting
to see the results of the efforts required to transition HST from a
development stage company to a revenue producing endeavor. The
Company has spent the past several months grooming relationships,
investing in research and development, and implementation of our
overall strategic plan. With the finalization of our worldwide
licensing model, we will commence the next phase of our strategy
via international growth and at the same time continually
substantiate shareholder value.”
About HST Global, Inc.
HST Global, Inc. is an Integrated Biotechnology Health and
Wellness company that is developing and or acquiring a network of
Wellness Centers worldwide that are primarily focused on the
immunotherapy and alternative treatment of late stage cancer. In
addition, the company intends to acquire innovative products for
the treatment of late stage cancer. In this regard, the company
primarily focuses on immunotherapy and alternative product
candidates that are undergoing or have already completed
significant clinical testing for the treatment of late stage
cancer.
HST Global, Inc. wishes to inform readers that forward-looking
statements in this release are made pursuant to the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995.
Readers are cautioned that such forward looking statements involve
risks and uncertainties including, without limitation, unforeseen
changes in the course of research and development activities and in
clinical trials by others; possible acquisitions of other
technologies, assets or businesses; possible actions by customers,
suppliers, competitors, regulatory authorities; and other risks
detailed from time to time in the Company's periodic reports filed
with the Securities and Exchange Commission.
HST Global (PK) (USOTC:HSTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
HST Global (PK) (USOTC:HSTC)
Historical Stock Chart
From Jul 2023 to Jul 2024